Singapore biotech startups chase the American dream
Benjamin Cher
DeeperDive is a beta AI feature. Refer to full articles for the facts.
SINGAPORE biotech startups are looking to the US as their next market for expansion, tapping the large population size and market opportunities to match.
Home-grown company Lucence, for one, recently secured Medicare reimbursement approval. The biotech startup’s blood test to detect lung cancer was approved by one of the world’s largest health insurance providers, opening the door for other insurance providers to follow suit.
“What we are looking at here in terms of blood tests… is already a US$10 billion market here in the US,” said Tan Min-Han, founder and chief executive officer of Lucence.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Beijing’s calculated silence on the Iran war
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance